Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why PTC Therapeutics, Inc. Shares Dipped

By Sean Williams - Mar 7, 2014 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

PTC Therapeutics shares sink after it reports its fourth-quarter results. Here what shareholders should really be focused on instead.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of PTC Therapeutics ( PTCT -3.31% ), a biopharmaceutical company developing small-molecule drugs to treat cancer, neuromuscular disorders, and infectious diseases, dropped as much as 15% after reporting its fourth-quarter results after the closing bell last night.

So what: For the quarter, PTC Therapeutics reported a 34% decline in revenue to $4.4 million as both collaboration and grant revenue fell from the year-ago quarter. Total operating expenses, however, soared by 77% to $22.5 million due to the initiation of its confirmatory phase 3 trial involving ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD), as well as higher general and administrative expenses. The combination of lower revenue and higher expenses ballooned its net loss to $17.9 million, or $0.75 per share, from $6.3 million in the fourth quarter of 2012. By comparison, Wall Street anticipated a much narrower loss of $0.57 per share.

Looking ahead, PTC Therapeutics is forecasting total operating expenses of $85 million-$95 million in fiscal 2014, and plans on ending the year with $175 million-$185 million in cash, cash equivalents, and marketable securities.

Now what: Generally speaking, earnings reports tend to be non-events for clinical-stage biopharmaceutical companies. But considering how far PTC's share price has run and how quickly it could burn through its cash if its losses continue to surpass the Street's forecast, the move lower today does make sense. The big event that has share-moving potential for PTC won't be coming until mid-2015. That's when PTC Therapeutics will be releasing the top-line data from its 48-week confirmatory trial using ataluren for nmDMD. Shareholders might find the lack of catalysts leading up to this data to be few and far between, but this is, nonetheless, where investors' focus should remain.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
PTCT
$35.93 (-3.31%) $-1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.